PCOS Is Now PMOS: The 2026 Rename, Explained for Women

In May 2026, polycystic ovary syndrome was officially renamed polyendocrine metabolic ovarian syndrome through a Lancet consensus involving 56 international organisations and more than 22,000 patient and clinician voices. The new acronym is PMOS. The diagnostic criteria did not change. The clinical condition did not change. If you have a PCOS diagnosis, you have a PMOS diagnosis. The name became more accurate; the experience of having the condition is what it always was.

The "polycystic" in PCOS was never accurate

The word "polycystic" describes the wrong thing. When a clinician orders an ovarian ultrasound for someone with suspected PCOS, what shows up is not a collection of cysts. It is a higher-than-typical number of small antral follicles, sometimes arranged in a string-of-pearls pattern along the ovarian surface. These are not cysts in the medical sense. They are follicles, the structures the body builds every cycle in the process of releasing an egg. In PMOS, this follicular maturation tends to stall, leaving more of them visible at any given moment.

A companion paper to the 2026 Lancet consensus, published in JAMA Internal Medicine, addressed the cyst question directly. The authors looked at whether women with PMOS actually have more pathological ovarian cysts than the general population. They do not. The visible "polycystic" appearance is a misnomer, and it has been one for decades.

The misnomer has done damage. It has driven women to ask about cyst removal that was never needed. It has confused patients reading their own ultrasound reports. It has implied a kind of pathology, cysts as masses, as ovarian damage, as something to be cut out, that does not match what the condition is. The 2026 rename removed the word because the word was wrong.

What "polyendocrine metabolic ovarian" names

The new name does three pieces of work.

"Polyendocrine" puts the hormonal system at the centre. PMOS involves more than one endocrine pathway, including ovarian hormones (androgens, oestrogen, progesterone), pituitary hormones (LH, FSH), pancreatic insulin signalling, and adrenal androgens. Naming the condition endocrine first is a structural choice. It names the most fundamental layer of what is happening.

"Metabolic" names what is now well-established as a defining feature, not a complication. Insulin resistance is present in about 85 percent of people with PMOS and in about 75 percent of women with PMOS at a lean body weight, per the 2026 Lancet consensus. Cardiometabolic risk is elevated even in pre-menopausal women. These are not downstream effects of an ovarian problem. They are part of how the condition shows up at the biological level, and the new name reflects that.

"Ovarian" stays because the ovary is genuinely involved. Disordered follicular maturation, irregular or absent ovulation, and altered ovarian hormone production are all part of the picture. What "ovarian" no longer implies, in PMOS, is the misnamed pathology of "polycystic." The ovaries are part of the condition. They are not the site of cysts.

What the new name leaves out is also a decision. Hair, acne, mood, sleep, fertility, and the psychological weight of living with the condition are all real features of PMOS. The 2026 consensus framed these as downstream of the endocrine and metabolic core, not as co-equal pillars of the diagnosis. This is a clarity choice, not a dismissal. The clinical and lived reality of these features is unchanged. The renaming team chose to name the cause-level layer, on the view that everything else flows from it.

How the rename happened

The rename was not announced. It was negotiated.

The work began more than 14 years ago, well before the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, the document that still anchors PMOS diagnostic criteria, was even drafted. By the time the 2023 Guideline published, the case for renaming had built enough momentum that a formal global consensus process became the obvious next step. The Monash University Centre for Research Excellence, which had led the 2023 Guideline, led this process as well.

The consensus involved 56 international academic, clinical, and patient-advocacy organisations. It pulled in more than 22,000 patient and clinician voices through surveys and structured workshops. Two formal consensus meetings, the first in November 2025 and the second in February 2026, narrowed dozens of candidate names down to three finalists, and then to one. The shortlist was tested for clinical accuracy, plain-language accessibility, and freedom from unintentional collisions in multiple languages. (One alternative, EMOS, was ruled out partly because the acronym overlapped with a subcultural music term.)

Two patient advocacy organisations did not sign on. PCOS Challenge in the United States and the PCOS Nutrition Center cited concerns about the costs of rebranding for small advocacy and clinical organisations, the open question of a possible male phenotype, and the broader disruption to a community that had built years of work under the PCOS name. Their dissent does not change the consensus, but it is part of the public record of how the change was negotiated.

Funding for the consensus process itself came from the Australian National Health and Medical Research Council, the UK patient advocacy organisation Verity, and the AE-PCOS Society. No pharmaceutical company funded the consensus. Several individual authors did declare honoraria from pharmaceutical companies with adjacent commercial interests, including Novo Nordisk and Eli Lilly (both GLP-1 manufacturers), Astellas, Ferring, Gedeon Richter, Bayer, and Exeltis. This is normal for senior endocrinology authors and is disclosed in the paper. It matters as context, not as a reason to discount the consensus.

The final paper, "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process," was published in The Lancet on May 12, 2026. It is open access. Anyone can read it.

What the rename does not change

The new name does not change the diagnosis. The 2023 International Guideline, which still defines who has PMOS and who does not, has not been updated. Adult diagnostic criteria continue to require two of three: clinical or biochemical hyperandrogenism, oligo-anovulation, and polycystic ovary morphology on ultrasound. Adolescent criteria continue to require both hyperandrogenism and oligo-anovulation, with no ultrasound criterion. (For plain-language definitions of these terms, see the PMOS glossary.)

The condition itself is the same. The biology is the same. The lived experience is the same. The treatments that were appropriate yesterday are appropriate today. The labs that were ordered yesterday will be ordered today. If you had a PCOS diagnosis on May 11, 2026, you had a PMOS diagnosis on May 13, 2026. Nothing about your body changed. Nothing about your care changed.

This is the most important thing to know.

What the rename validates

If the rename does not change anything clinically, what does it do? It pulls long-standing science forward.

For at least two decades, researchers, clinicians, and patient advocates have argued that PCOS is fundamentally a multisystem endocrine and metabolic condition, not a primarily gynaecological one. The 2023 Guideline already made this case in detail. The rename writes the case into the name itself, which means it now travels with every clinical encounter, every coding decision, every research grant title.

A few specific shifts deserve attention.

Insulin resistance moves from a "common feature" to a Tier 1 mechanistic anchor. The 2026 Lancet consensus cites 85 percent prevalence of insulin resistance and compensatory hyperinsulinaemia in people with PMOS overall. In lean women with PMOS, defined as a body mass index of 25 or below, the prevalence is approximately 75 percent. This is the highest-quality summary number now available, and it changes the conversation.

The lean PMOS presentation, in particular, has long been dismissed in clinical settings. Women at a normal body weight reporting irregular cycles, fatigue, cravings, and androgen-driven symptoms have often been told they cannot have the condition because their weight is "fine." That dismissal now sits against Tier 1 evidence: three out of four lean women with PMOS have insulin resistance. The fasting glucose test that often comes back normal in this group misses what fasting insulin and HOMA-IR catch. This was true before the rename. It is harder to ignore after it.

Cardiometabolic risk also gets the gravity it deserves. The Lancet consensus consolidated evidence showing that in predominantly pre-menopausal women with PMOS, the composite risk of cardiovascular events is meaningfully elevated, with an odds ratio of 1.68. For myocardial infarction, the odds ratio is 2.50; for stroke, 1.71. These numbers are not designed to alarm. They are designed to make the case for early, integrated metabolic and cardiovascular care, including for younger women who are often told they are "too young" to think about heart health.

And the multisystem framing, endocrine and metabolic and ovarian, with reproductive, dermatological, and psychological features flowing from it, finally has a name to live in.

What is still uncertain

The renaming does not resolve every open question about the condition. A few worth naming.

Subtypes. Researchers have been working for years to identify clinically meaningful subtypes of PMOS, patterns of presentation that respond differently to treatment, carry different risk profiles, or originate from different underlying mechanisms. The 2026 Lancet consensus acknowledges this work as a recognised direction but does not lock in a subtype classification. The 2028 International Guideline, planned as the next major update, may begin to do so.

A possible male phenotype.PMOS, as currently defined, requires ovaries to manifest. But the underlying endocrine and metabolic features have analogues in some men, particularly around early-onset insulin resistance, androgen patterns, and metabolic risk. Whether there is a meaningful "male PMOS" or a related but distinct condition is an open research area. The renaming does not answer the question, but the new name's reduced emphasis on ovarian anatomy may make the question more legible.

Adoption timeline. Medical terminology changes are usually slow. The renames of several pancreatic and thyroid subtypes took roughly a decade each to filter through coding systems, electronic health records, lab reports, insurance forms, and consumer-facing health content. PMOS will likely follow a similar curve. The 2028 Guideline update is the next inflection point. Full adoption probably extends well past it.

What this means in practice: PMOS will be the right word in published research, expert consensus, and updated clinical training over the next 12 to 24 months. PCOS will continue to appear in patient charts, search engines, insurance documentation, and everyday speech for considerably longer.

What to expect over the next two years

A few practical notes for the transition.

Your clinician may not have heard yet. Medical journals reach practising clinicians at very different rates depending on specialty, geography, and individual reading habits. An endocrinologist with a PMOS-adjacent research interest probably knew about the rename within hours of the Lancet publication. A general practitioner managing thirty patients a day may not have heard for months. This is normal. If you mention PMOS and your clinician looks blank, the most useful thing you can do is name both terms in the same sentence. I have what is now called PMOS, what used to be called PCOS. The clinical conversation proceeds as it would have before.

Your insurance, lab portals, and electronic health records will say PCOS for a while. None of those systems update overnight. Diagnostic codes, billing references, and patient-facing terminology in commercial healthcare technology will continue to use PCOS through at least the 2028 Guideline update, and likely longer. Your records do not need to be re-coded.

Search engines will be inconsistent. If you search for PMOS in the first few months after the rename, results will be patchy. If you search for PCOS, the older, larger, less updated body of content will surface. Use both terms when you research, and weight more recent sources higher.

Cyster will use both names during this transition. In long-form knowledge content like this article, the new name leads. In short copy and on the surfaces where search familiarity matters most, the older name still appears. This is a choice about meeting readers where they are while teaching where the science has moved. Two years from now, the balance will probably flip.

And, since the question comes up: the brand name "Cyster" derives from "sister," not from "cyst." It predates the rename and is not affected by it.

What to ask a clinician

If the rename comes up in a clinical conversation, two or three questions are worth having ready.

Has the way you think about my care changed because of the rename? The honest answer is almost always no. The new name does not change the diagnostic criteria or the treatment options. Asking explicitly often clarifies more than it confuses.

Are there things you think about differently now because of the new framing? Some clinicians have been treating the condition as multisystem and metabolic for years. Some are still oriented around the older cysts-and-cycles framing. The answer will tell you which kind of practice you are in, and whether you are getting the integrated metabolic and cardiovascular attention the 2026 consensus emphasises.

Are my labs and tests organised around what the current evidence considers central? This is the indirect way to ask about fasting insulin, HOMA-IR, lipid panels, and cardiovascular screening, particularly if those have not been part of your past workups.

There is no need to push your clinician to change vocabulary. The vocabulary will catch up. What matters is whether your care reflects the science the rename codifies.